Management of Peritoneal Carcinomatosis With Cytoreductive Surgery Combined With Intraperitoneal Chemohyperthermia at a Novel Italian Center.
HIPEC
colon cancer
gastric cancer
ovary cancer
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
25
03
2020
revised:
10
04
2020
accepted:
16
04
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
Peritoneal carcinomatosis (PC) is a common manifestation of many gastrointestinal (GI) malignancies and is an advanced stage that is often associated with disseminated disease. Considerable progress has been made to achieve safe elimination of macroscopic disease using cytoreductive surgery (CRS) and more recently in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of microscopic disease or disease with minimal volume. The aim of this study was to assess the effects of such procedures on the quality of life (QoL), the long-term benefit and the functional status of the treated patients. Data from patients who underwent CRS-HIPEC for peritoneal metastasis (PM) at our center from November 2016 to November 2018 were analyzed retrospectively. The drugs administered were mitomycin and cisplatin. Quality of life (QoL) was assessed using the Euroquol-5D-5L and National Comprehensive Cancer Network Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index v2 questionnaires before CRS-HIPEC, and 1, 3 and 6 months after were administered. In our series, the survival efficacy of CRS plus HIPEC was confirmed in the treatment of primary and secondary peritoneal pathologies, particularly in ovarian cancer, although larger studies are needed to investigate its role in the pathology of gastric, colonic and rectal cancer. The QoL data were promising, with essentially stable values between the preoperative and the 1-month follow-up, but with incremental benefits from the second to the third month.
Sections du résumé
BACKGROUND
BACKGROUND
Peritoneal carcinomatosis (PC) is a common manifestation of many gastrointestinal (GI) malignancies and is an advanced stage that is often associated with disseminated disease. Considerable progress has been made to achieve safe elimination of macroscopic disease using cytoreductive surgery (CRS) and more recently in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of microscopic disease or disease with minimal volume. The aim of this study was to assess the effects of such procedures on the quality of life (QoL), the long-term benefit and the functional status of the treated patients.
PATIENTS AND METHODS
METHODS
Data from patients who underwent CRS-HIPEC for peritoneal metastasis (PM) at our center from November 2016 to November 2018 were analyzed retrospectively. The drugs administered were mitomycin and cisplatin. Quality of life (QoL) was assessed using the Euroquol-5D-5L and National Comprehensive Cancer Network Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index v2 questionnaires before CRS-HIPEC, and 1, 3 and 6 months after were administered.
RESULTS
RESULTS
In our series, the survival efficacy of CRS plus HIPEC was confirmed in the treatment of primary and secondary peritoneal pathologies, particularly in ovarian cancer, although larger studies are needed to investigate its role in the pathology of gastric, colonic and rectal cancer. The QoL data were promising, with essentially stable values between the preoperative and the 1-month follow-up, but with incremental benefits from the second to the third month.
Identifiants
pubmed: 32606183
pii: 34/4/2061
doi: 10.21873/invivo.12008
pmc: PMC7439894
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2061-2066Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
J Clin Oncol. 2010 Jan 1;28(1):63-8
pubmed: 19917863
Ann Surg. 2009 Jun;249(6):900-7
pubmed: 19474692
Abdom Imaging. 2010 Dec;35(6):701-7
pubmed: 19784697
J Clin Oncol. 2004 Aug 15;22(16):3284-92
pubmed: 15310771
Dis Colon Rectum. 1987 Oct;30(10):772-9
pubmed: 2820671
J Clin Oncol. 2009 Feb 10;27(5):681-5
pubmed: 19103728
Lancet Oncol. 2006 Jan;7(1):69-76
pubmed: 16389186
Ann Surg. 1995 Jan;221(1):29-42
pubmed: 7826158
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Clin Oncol. 2012 Jan 20;30(3):263-7
pubmed: 22162570
Eur J Surg Oncol. 2012 Jun;38(6):509-15
pubmed: 22475555
Curr Oncol. 2016 Jun;23(3):e266-75
pubmed: 27330364
Cancer. 2010 Dec 15;116(24):5608-18
pubmed: 20737573
Dis Colon Rectum. 1993 Apr;36(4):323-9
pubmed: 8458256
World J Gastroenterol. 2013 Nov 7;19(41):6979-94
pubmed: 24222942
Dis Colon Rectum. 2017 Oct;60(10):999-1017
pubmed: 28891842
J Surg Oncol. 2014 Nov;110(6):666-9
pubmed: 24986323
J Clin Oncol. 2012 Jul 10;30(20):2449-56
pubmed: 22614976
Int J Colorectal Dis. 2018 Nov;33(11):1559-1567
pubmed: 30132068
Oncotarget. 2017 Apr 27;8(33):55657-55683
pubmed: 28903452
Ann Surg Oncol. 2008 Nov;15(11):3065-72
pubmed: 18712450
Ann Surg. 2013 Jun;257(6):1065-71
pubmed: 23299520
Langenbecks Arch Surg. 2014 Jan;399(1):41-53
pubmed: 24249036
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
Ann Oncol. 2011 Oct;22(10):2250-6
pubmed: 21345939
Ann Surg Oncol. 2013 Dec;20(13):4224-30
pubmed: 23897008
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Cancer Treat Res. 1996;82:79-100
pubmed: 8849945
Cancer Treat Rev. 2013 Jun;39(4):321-7
pubmed: 23244778